CD180-targeted ADC / Corellia AI, Champions Oncology - LARVOL DELTA

CD180-targeting ADCs with a topoisomerase I inhibitor payload achieve strong efficacy in AML tumors (AACR 2026) - "All clinical and histopathological findings were mild and reversible, establishing a maximum tolerated dose of 60 mg/kg. The ADC also demonstrated excellent physicochemical stability and developability properties.Together, these findings support advancement of CD180-targeted ADC therapy into clinical development for patients with CD180-positive AML."

ADC • Clinical • IO biomarker • Acute Myelogenous Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology